Tirzepatide with B12
Compounded tirzepatide with cyanocobalamin
Written by Aaron CuhaReviewed Sep 2026
Also known as: Tirzepatide/cyanocobalamin, Tirz B12
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is compounded tirzepatide with vitamin B12 mixed in. It is the one blend on this site where somebody actually tested the chemistry, and they found a problem. Mixing the two makes a new substance that was not supposed to be there.
What people take it for
- Losing weight.
- Less nausea from the shot.
- More energy.
What the trials actually showed
No one has tested the mix in a person. But a lab did test the liquid. They bought compounded tirzepatide and B12 products from several places in the US market and ran them through their machines. They found a widespread impurity nobody had seen before. It comes from a chemical reaction between the tirzepatide and certain forms of B12. What that impurity does in a body is unknown, and the paper says so plainly. One thing you should know. The people who ran those tests all work for Eli Lilly, which sells the brand name tirzepatide and competes with compounders. That is a real conflict and it is printed in the paper. It is also the only chemistry anyone has published on these mixes, and nobody has published anything that disagrees. The tirzepatide half on its own is strong. In SURMOUNT-1, people lost 20.9 percent of their body weight on the top dose over 72 weeks, against 3.1 percent on a dummy shot. The math: a common vial is 20 mg per mL tirzepatide with 0.5 mg per mL B12. A 5 mg dose is a quarter of a mL, which carries 125 micrograms of B12.
What people report
Reports, not trial results
The good
- Hunger goes quiet.
- Weight comes off fast.
The bad
- Nausea, constipation and reflux.
- Sulphur burps and feeling full too early.
- People got nervous when the impurity finding went public and moved back to single ingredient vials.
- Nobody tests these vials for strength or purity before they are sold, so you do not know what is in yours.
Where these come from: The stomach side effects come from the trial tables. The rest comes from patient forums and is just people talking. The impurity finding is a published lab study and is listed on this page.
My bottom line
Somebody looked at this one, and what they found was a reaction nobody can explain the effects of. The conflict of interest is real and so is the chemistry. I would take the vitamin separately.
An opinion, not a finding. I am a coach, not a doctor.
Overview
The one blend in this database with a published chemical reason not to mix it. Laboratory testing of compounded tirzepatide plus B12 products from multiple sources found a widespread, previously unidentified impurity formed by a reaction between the peptide and certain B12 analogues. The testing was done by the branded manufacturer, which is a disclosed conflict, and it is the only published chemistry on these premixes.
Most pages in this section have to say that nobody has looked. This one is different: somebody looked, and they found something.
Samples of compounded tirzepatide combined with B12, obtained from various sources in the US market, were tested by several analytical methods and assessed for peptide-related impurities. The testing identified a widespread and previously unidentified impurity resulting from a chemical reaction between tirzepatide and certain analogues of vitamin B12. The authors are employees of Eli Lilly, which makes the branded tirzepatide and has an obvious commercial interest in the compounded market. That conflict is disclosed in the paper and it is real. It is also not a reason to ignore a chemistry result, because the finding is a measurement rather than an opinion, and no competing analysis has been published.
What is not known is what the impurity does. The paper states that the clinical effects are unknown: whether it affects binding at the GLP-1 and GIP receptors, whether it is toxic, whether it provokes an immune response, and how it is absorbed and eliminated. That is an unusually honest set of unknowns and it is also exactly the problem. An untested molecule at substantial levels in a weekly injection is not a theoretical concern.
The arithmetic on a common multi-dose preparation: tirzepatide 20 mg/mL with cyanocobalamin 0.5 mg/mL in a 5 mL vial. A 5 mg tirzepatide dose is 0.25 mL, which carries 125 micrograms of B12. A 2.5 mg starting dose is 0.125 mL and 62.5 micrograms. The B12 is 2.5% of the tirzepatide by mass at every dose, so once again the vitamin amount is set by the incretin dose and not by anything about the person receiving it.
The tirzepatide half itself is strongly evidenced. In SURMOUNT-1, mean weight change at 72 weeks was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo, with 57% of the 15 mg group losing 20% or more of body weight against 3% on placebo. That trial used tirzepatide alone.
Mechanism of action
Tirzepatide is a dual GIP and GLP-1 receptor agonist that reduces appetite and slows gastric emptying. Cyanocobalamin is a B12 form used to correct deficiency. The mechanistically important fact on this page is not either drug's action but the reaction between them: analytical work found a new species formed from the peptide and certain B12 analogues in the same solution.
Human evidence
No human study of the premix. The tirzepatide half has large randomised trials and the impurity has no human data at all, which is the substance of the concern.
- The premix: no published clinical study, no registered trial.
- Tirzepatide alone: 20.9% mean weight loss on 15 mg at 72 weeks against 3.1% on placebo.
- The impurity: identified analytically across multiple market sources, with clinical effects explicitly stated to be unknown.
- B12: replacement normalises serum levels in over 90% of deficient patients at eight weeks.
What this does not tell you: Nobody has measured what the impurity does in a person, at receptor level, in the immune system, or over time. That is not a reassurance, it is the reason the finding was published.
What it has been measured to do
Measured in people
Goals Tirzepatide with B12 has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Losing weightno headcount stated · 1 study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with Tirzepatide with B12, what they expect, and what goes wrong. The full account, including the negative reports, is below.
32 of the 36 indexed goals have no study of any kind behind Tirzepatide with B12
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about Tirzepatide with B12 and one of these did not come from a study cited here.
Reading the research record
Two things must be held at once here and they pull in opposite directions. The chemistry finding is real, published, peer reviewed and unrebutted. It is also authored entirely by employees of the company whose branded product competes with the compounded market, and that company has litigated and campaigned against compounders. Both facts belong on the page. The appropriate response to a conflicted finding is an independent replication, and none has been published.
The second point is about why the vitamin is there at all. On the semaglutide side the reasons given are nausea and energy, neither of which has a trial. On the tirzepatide side the same reasons are given, plus a regulatory one: a preparation with an added ingredient is not an exact copy of an approved drug. If that is the actual motive, then the impurity finding describes a patient bearing an unquantified chemical risk for a regulatory convenience.
The evidence, charted
Fig. 1a · evidence scale
2human studies cited, participant count not stated
participants not stated
No participant total is drawn, because none of the human citations on this page gives one. Read the citations below for what each study measured.
Participant counts are read from the citation lines on this page. Where a line states no number, nothing is counted for it rather than estimated.
Fig. 1b · evidence mix
2 of 4 citations here are human work, the rest are not.
- Human · given to people250%
- In vitro · cells, tissue or a dish125%
- Review · summarises other work125%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2020 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the mixture. The incretin component supports weekly dosing; no pharmacokinetic study of the premix has been published, and the impurity's behaviour is unknown.
No amino acid sequence is on file for Tirzepatide with B12, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
No mass split can be drawn for this blend
Sellers do not publish a consistent vial size for Tirzepatide with B12, so the share of each component is not knowable from the outside. Splitting the bar evenly would invent the number this page exists to question.
- Tirzepatideamount not stated
- Cyanocobalaminamount not stated
Component list from the product labels we hold. Amounts are label mass, never a dose.
Key studies & citations
- In vitro2026
A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications
Compounded tirzepatide plus B12 samples from various US market sources were tested by several analytical methods and assessed for peptide-related impurities. Testing identified a widespread, previously unidentified impurity resulting from a chemical reaction between tirzepatide and certain B12 analogues. The paper states that the clinical effects of the impurity are unknown. All five authors are Eli Lilly employees, disclosed in the paper, and Lilly markets the branded tirzepatide.
Expert Opinion on Drug Safety - Human2022
Tirzepatide Once Weekly for the Treatment of Obesity
SURMOUNT-1. Mean percentage weight change at week 72 was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg weekly, against 3.1% on placebo. 57% of the 15 mg group lost 20% or more of body weight against 3% on placebo. Gastrointestinal events were the most common adverse events and were mostly mild to moderate. Tirzepatide alone, with no vitamin co-administered.
New England Journal of Medicine - Human2020
Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12)
In patients with documented deficiency, oral and intramuscular B12 both normalised serum B12 in well above 90% of patients at eight weeks. B12 evidence is replacement evidence in tested, deficient people.
BMJ Open - Review2026
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA's statement on compounded and other unapproved GLP-1 products, covering adverse event reports, dosing errors and the absence of agency review for safety, effectiveness or quality.
FDA
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Nausea, constipation and reflux, the same pattern as the branded product.
- Sulphur burps and early fullness.
- A pink or red tint to the solution from the B12, which people use to identify the product.
- No perceived difference from non-B12 compounded preparations.
- Anxiety after the impurity finding was publicised, and a shift back towards single-ingredient compounded vials.
Sources: Trial adverse event tables for the gastrointestinal pattern. The rest from forums including r/tirzepatidecompound and telehealth patient communities, uncontrolled and self-reported.
Frequently asked questions
Is there actually something wrong with mixing tirzepatide and B12?
Published analytical testing of market samples found a widespread, previously unidentified impurity formed by a chemical reaction between tirzepatide and certain B12 analogues. What that impurity does in a person is unknown and the paper says so.
Who did that testing?
Eli Lilly employees, disclosed in the paper. Lilly markets the branded tirzepatide and competes with compounders. That conflict is real and should be weighed. No independent replication has been published, and no competing analysis has either.
How much B12 is in my dose?
On a common 20 mg/mL tirzepatide with 0.5 mg/mL cyanocobalamin preparation, a 5 mg dose is 0.25 mL and carries 125 micrograms of B12. The vitamin is 2.5% of the peptide by mass at every dose, so the amount tracks your tirzepatide dose and not your B12 status.
Should I switch to a single-ingredient vial?
That is the version with one fewer unknown in it. This page does not give medical advice, and the decision belongs with your prescriber, but the reason the vitamin is present is worth asking about before accepting the reaction chemistry that comes with it.
Does the tirzepatide still work in these preparations?
Compounded products are not tested for potency or impurity profile before sale, so the honest answer is that nobody outside the pharmacy knows what is in a given vial. The 20.9% weight loss figure people quote comes from a trial of the approved product.